Insulet Corporation
NASDAQ: PODD · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-05
Insulet Corporation (PODD) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-31.82M | $-50.37M | $-82.61M | $-49.32M | $-35.63M | $-25.45M | $-29.06M | $3.35M | $8.92M | $-12.55M | $15.91M | $41.30M | $35.90M | $98.40M | $84.00M | $-68.10M | $119.00M | $145.70M | $430.30M | $569.30M |
| Capital expenditures | $13.14M | $10.09M | $10.05M | $3.14M | $6.55M | $11.11M | $10.99M | $7.31M | $11.49M | $10.61M | $22.11M | $77.23M | $162.35M | $170.90M | $166.50M | $122.70M | $157.30M | $75.60M | $124.90M | $191.60M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $1.52M | $3.37M | $4.20M | $5.06M | $7.73M | $9.92M | $12.68M | $22.52M | $19.18M | $23.62M | $31.90M | $37.50M | $28.70M | $35.90M | $34.40M | $40.90M | $48.30M | $69.30M | $62.70M |
| Free cash flow | $-44.96M | $-60.46M | $-92.66M | $-52.46M | $-42.17M | $-36.57M | $-40.05M | $-3.96M | $-2.57M | $-23.16M | $-6.20M | $-35.93M | $-126.45M | $-72.50M | $-82.50M | $-190.80M | $-38.30M | $70.10M | $305.40M | $377.70M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $8.60M | $98.50M | $23.50M | — | $10.60M | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $-19.32M | $-36.66M | $92.43M | $1.47M | $-28.52M | $14.50M | $135.40M | $-158.67M | $98.30M | $703.50M | $-110.10M | $-112.40M | — | — | — |
Frequently asked questions
What is Insulet Corporation's revenue?
Insulet Corporation's trailing twelve-month revenue is $2.90B. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is PODD?
In its most recent fiscal year, PODD ran a gross margin of 71.63%, an operating margin of 17.50%, and a net margin of 9.12%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does PODD generate?
PODD produced $377.70M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is PODD's balance sheet healthy?
PODD holds $716.10M in cash and equivalents against $930.80M in long-term debt, on $1.52B of shareholder equity. That debt is best read against the cash flow the business throws off each year.